ライフサイエンスコーパス: homograft

1 r outflow reconstruction was achieved with a homograft.

2 also grafted to the left carotid artery as a homograft.

3 egarding evolving pathology in the pulmonary homograft.

4 ss-clamp times, and insertion of a pulmonary homograft.

5 ncludes augmentation of the aortic arch with homograft.

6 fts and in the recanalized lumen of occluded homografts.

7 monstrated in 10 of 10 allografts and 5 of 6 homografts.

8 owth and tumor weight of murine liver cancer homografts.

9 degree to that seen with the previous group (homografts 1.5+/-0.3 cm, autografts 1.4+/-0.2 cm).

10 24 patients aged 40+/-11 years) or an aortic homograft (23 patients aged 37+/-11 years) for rereplace

11 Implant substrate included homograft (41%), bioprosthesis (30%), native right ventr

12 astolic diameter was similar in both groups (homografts, 5.0+/-0.9 cm; autografts, 5.2+/-0.6 cm; P=NS

13 roke volumes were maintained in both groups (homografts 67+/-15 mL, autografts 67+/-16 mL; P=NS).

14 ypass graft and aortic root replacement with homograft and 6 weeks of intravenous ampicillin and gent

15 site valved conduits made from cryopreserved homograft and polytetrafluoroethylene (PTFE) in 66 cases

16 ter MVR is higher than after AVR; after AVR, homografts and bioprosthesis have similar rates of SVD.

17 (39.5%) a mechanical prosthesis, 70 (4.2%) a homograft, and 350 (20.7%) a transcatheter heart valve.

18 ial valves, stentless porcine valves, aortic homograft, and pulmonary autograft.

19 tic root replacement (Ross procedure) versus homograft aortic root replacement in adults.

20 ne-to-one ratio to receive an autograft or a homograft aortic root replacement in one centre in the U

21 ndomly assigned to receive an autograft or a homograft aortic root replacement.

22 Aortic valve replacement (AVR) with homograft aortic valve was introduced by Ross in 1962 an

23 fied as O. turbata (four from the blood of a homograft aortic valve-associated endocarditis patient a

24 Although the aortic homografts are durable, with low incidence of infection

25 Homografts are not immune to prosthetic bacterial endoca

26 it interventions and death when aortic valve homografts are used in the RV-PA conduit.

27 Pulmonary homografts are used more frequently in cardiac surgery.

28 l as function of the autograft and pulmonary homograft, are needed.

29 atric Ross procedure, mechanical AVR (mAVR), homograft AVR (hAVR), and/or bioprosthetic AVR were cons

30 Like the pulmonary autograft, homograft AVR results in an excellent hemodynamic outcom

31 l AVR, 10.9% a bioprosthesis AVR, and 3.5% a homograft AVR, with Ross patients being significantly yo

32 Homograft calcification occurs significantly faster than

33 Homografts can be considered when extensive aortic annul

34 , whereas there was no significant change in homograft circumference.

35 SAE were more frequent in homograft conduit than other RVOT substrates, although S

36 ars in patients >5 years), with younger age, homograft conduit, conduit diameter < or =10 mm, diagnos

37 ilure (valve explant or late death), and (3) homograft dysfunction (homograft insufficiency or homogr

38 Freedom from reintervention for homograft dysfunction was 87% at 8 years; freedom from a

39 Homograft efficacy and durability were similar in RVOT a

40 ncreased to a similar amount in both groups (homografts: end-diastolic volume 145+/-34 mL, end-systol

41 tis in 14 patients (0.11% per patient-year), homograft endocarditis in 11 patients (0.08% per patient

42 ith functional analysis, we show that Slwox4 homografts fail to form xylem bridges across the junctio

43 Three patients required re-replacement for homograft failure (5.4%); one of these patients died.

44 nd points included (1) patient survival, (2) homograft failure (valve explant or late death), and (3)

45 donor warm ischemic time as risk factors for homograft failure and dysfunction, whereas, Z: value <2

46 , and previous procedure as risk factors for homograft failure and dysfunction.

47 d extracardiac operative technique predicted homograft failure but not dysfunction.

48 Freedom from homograft failure was 74+/-4% at 5 years and 54+/-7% at

49 reedom from patient death or reoperation for homograft failure was 82% +/- 7% at 1000 days and 77% +/

50 Homograft failure was defined as requirement for replace

51 The only significant predictor of homograft failure was postoperative endocarditis (p < 0.

52 n of each variable for patient mortality and homograft failure.

53 an evolution away from use of cryopreserved homografts for LVOT reconstructions except when needed f

54 Among 205 patients receiving cryopreserved homografts for reconstruction of the RVOT between Novemb

55 the autograft group versus three (3%) in the homograft group (p=0.621).

56 Freedom from reoperation was 93+/-4% in the homograft group versus 100+/-0% in the freestyle group a

57 Hazard ratio for death in the homograft group was 4.61 (95% CI 1.71-16.03; p=0.0060).

58 One early death occurred in the homograft group, and 1 late (7 months) death occurred in

59 died in the autograft group versus 15 in the homograft group.

60 in the autograft group versus 83% (4) in the homograft group.

61 For groups with FGS, long-surviving renal homografts had a significantly smaller mean glomerular d

62 The use of cryopreserved homografts has improved reconstruction of the right vent

63 ic material, nonvascularized allografts, and homografts have been used to address this dilemma.

64 t 5 1/2 years; in surviving patients, 89% of homografts have continued to function well.

65 s comprised of both native aortic tissue and homograft, have not been characterized.

66 septal hypertrophy in 2, overlying pulmonary homograft in 1, and overlying ventricular septal defect

67 We also compared all procedures except the homograft in a matched population of young adults, where

68 time, smaller homograft size, use of aortic homograft in the older patient, and extracardiac operati

69 mber 1985 and April 1999, the outcome of 220 homografts in 183 operative survivors was analyzed.

70 flow tract reconstruction was performed with homografts in 98.6% (n = 1189) and bioprostheses in 1.4%

71 s the evolution of a single surgeon's use of homografts in a mixed pediatric and adult practice.

72 late death), and (3) homograft dysfunction (homograft insufficiency or homograft stenosis).

73 , one surgeon implanted cryopreserved valved homografts into 149 patients--65 since December 1988.

74 th either a pulmonary autograft or an aortic homograft leads to a degree of persistent RV longitudina

75 r, there is concern that over time pulmonary homografts may develop stenosis secondary to low-grade i

76 ibited tumor growth in metastasis in a mouse homograft mode of melanoma and a patient-derived xenogra

77 The most commonly used homograft model is the B16 mouse melanoma.

78 vo using an immunocompetent Tsc2-null murine homograft model.

79 ergo aortic valve replacement with an aortic homograft or a pulmonary autograft were followed up echo

80 there was evidence of narrowing of the whole homograft or distal suture line in 14 of 15 patients, wi

81 een patients who had undergone either aortic homograft or pulmonary autograft surgery were studied be

82 A total of 20 patients received a stentless (homograft or Toronto) valve, and 13, a stented valve.

83 (PTFE) in 66 cases (54 pulmonary, 12 aortic homografts), other valved conduits in 14, and unvalved P

84 Homograft performance was evaluated by an extensive echo

85 Freedom from autograft and homograft reintervention after 15 years was 92.0% and 97

86 reintervention, autograft reintervention, or homograft reintervention and time-related valve function

87 Homograft reintervention occurred in 13% within 8 years.

88 ntion, 80.3% (95% CI, 71.9%-89.6%); and from homograft reintervention, 86.3% (95% CI, 79.0%-94.3%).

89 erior after the Ross procedure, the need for homograft reinterventions is an issue to take into accou

90 Survival and autograft-related and homograft-related reintervention.

91 ng surgical replacement for a putative total homograft-related structural failures rate of 11% at 5 1

92 ivariate analysis of patient-, surgery-, and homograft-related variables did not reveal any significa

93 nts undergoing either pulmonary autograft or homograft replacement of the aortic valve as part of a p

94 ge from valve repair to valve replacement to homograft replacement.

95 September 1, 1994, to May 31, 2001, compared homograft root replacement with the Ross procedure at a

96 Homograft roots exhibit significantly higher calcium sco

97 trate significantly higher calcium scores in homograft roots than freestyle at 1.5 years (P=0.02), 2

98 vely) were reduced postoperatively (P<0.05) (homografts: SE 1.5+/-0.4 versus 2.3+/-0.6 cm, SR 6.8+/-2

99 ge, longer donor warm ischemic time, smaller homograft size, use of aortic homograft in the older pat

100 Pulmonary homograft stenosis after the Ross operation is clinicall

101 Freedom from any pulmonary homograft stenosis at 7-year follow-up was 79.7%, with i

102 raft dysfunction (homograft insufficiency or homograft stenosis).

103 eoperation for rapidly progressive pulmonary homograft stenosis; in all 4, there was macroscopic and

104 ted: mechanical valves, cryopreserved aortic homograft, stented heterograft, and pulmonary autograft

105 of mechanical valves, bioprosthetic valves, homografts, stented valves, the Ross operation, and fina

106 response to the long-term results of aortic homografts, stentless porcine valves were introduced as

107 m from aortic valve dysfunction was lower in homografts than freestyle roots (P=0.06).

108 ative inflammatory reaction to the pulmonary homograft that leads to extrinsic compression and/or shr

109 iography protocol: in surviving patients and homografts, three valved conduits were judged to have se

110 Using a homograft tumor model in Balb/c mice, we discovered that

111 Aortic homograft type and extracardiac operative technique pred

112 There were 150 pulmonary and 70 aortic homografts used.

113 efficacy of angioplasty of obstructed RV-PA homografts using ultra-noncompliant (UNC) or ultrahigh-p

114 Z: value <2 and aortic valve type predicted homograft valve failure.

115 Patient weight, use of an aortic homograft valve in the conduit, stage I palliation withi

116 olate from the second patient and one of the homograft valve isolates differ from O. turbata and C. h

117 olates from the first patient and six of the homograft valve isolates represent a single clone of O.

118 from cerebrospinal fluid, and one each from homograft valve, lip wound, and pilonidal cyst) were com

119 Cryopreserved homograft valves are an imperfect but satisfactory biolo

120 ored the long-term function of cryopreserved homograft valves used for reconstruction of the right ve

121 Homograft valves used for RVOT reconstruction provide ef

122 carditis patient and seven from contaminated homograft valves) and one CDC group A-3 strain from the

123 nts were prospectively randomized to undergo homograft versus freestyle total aortic root replacement

124 ong-term degree and rate of calcification of homografts versus Medtronic freestyle aortic roots to de

125 hocardiographic examination of the pulmonary homograft was performed immediately after surgery, then

126 Homografts were used in 117 patients, xenografts in 103

127 al comparing pulmonary autografts and aortic homografts who have had previous aortic valve replacemen

128 rwent 76 procedures for angioplasty of RV-PA homografts with UNC Atlas balloons.

129 ute hemodynamic changes after angioplasty of homografts with UNC balloons included significantly redu